KITLIVING
factors that is has in common with other
CGM solutions, such as accuracy, but
also taken into account the fact that these
currently leave something to be desired
in terms of usage. For example, we are
looking to have a reduced pain score with
this technology. As the microneedles are
only 1 mm deep, this should not cause
pain and lead instead to less inflammation
and reduced infection risk. Although only
at the early stages of research, our current
technologies do work in the clinical
research setting. We had prototypes that
were simply inserted by being pressed
into the skin with thumb pressure. We
expect to include some sort of applicator
for a commercial product, which will make
it even better to use. The forearm was the
site on the body that was used in the
feasibility trial. While that was perfectly
effective, we would want to test for use
in other areas. Ideally, if possible, anyone
could put it wherever suits you best. A
transmitter will be required so results can
be sent to a reader or compatible apps or
even insulin pumps, and our chemical and
engineering colleagues will be working
towards making the whole system as
small as possible."
As it stands, the project is at the early
phases of research, but a preliminary
study showed accuracy similar to that
of the most accurate commercially CGM
system currently available. Obviously
more research is needed, as well as
more funding and the timeframe for this
is unknown. Reddy explains, "We are
just at the very early stages, but having
said that the results so far have been very
encouraging. Next steps would involve
looking at sensor lifespan and evaluate
its use in the home setting i.e out of the
clinical research facility. We aim to make
the microneedle CGM a cost effective
solution so that more people with diabetes
can benefit from the clear benefits of
continuous glucose monitoring."
TOP: Concept imagary
of the microneedle CGM
technology being researched
at Imperial College. ABOVE:
A prototype worn on the arm.